What is CareDx's cash & equivalents?

CareDx (CDNA) reported cash & equivalents of $78.47M in Q1 2026.

How has CareDx's cash & equivalents changed year-over-year?

CareDx's cash & equivalents decreased by 12.1% year-over-year, from $89.3M to $78.47M.

What is the long-term trend for CareDx's cash & equivalents?

Over 5 years (2020 to 2025), CareDx's cash & equivalents has grown at a -13.3% compound annual growth rate (CAGR), from $134.94M to $65.98M.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

CareDx CDNA Cash & Equivalents

Cash & Equivalents at other companies

Thermo Fisher ScientificTMO

$3.28B-21.4%

Natera, Inc.NTRA

$1.09B+11.7%

NeoGenomicsNEO

$146.14M-57.8%

Personalis, Inc.PSNL

$73.59M+3.7%

GeneDx HoldingsWGS

$94.92M-5.7%

TransMedics Group, Inc.TMDX

$461.74M+48.9%

Other financials

Income statement

See full

Revenue$117.7M+39.0%

Operating income$1.2M+109%

Net income$2.8M+127%

EPS (diluted)$0.05+126%

Balance sheet

See full

Total debt$24.5M-19.1%

Total equity$313.5M-17.3%

Total assets$411.1M-16.0%

Cash flow

See full

Operating cash flow$4.3M+116%

CapEx$3.8M+134%

Free cash flow$514.0K+102%

Valuation

See full

Market cap$1.4B-9.6%

Enterprise value$1.35B-9.7%

P/S3.4×-1.1×

Profitability

See full

Gross margin65.5%—

Operating margin-3.9%-18.3pp

Net margin-2%-19.9pp

FCF margin-0%0.0pp

Returns & leverage

See full

Return on equity-2.4%-21.9pp

Debt / equity0.1×0.0×

Current ratio3.4×-0.7×

Where this comes from

Reported directly by CareDx in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: CareDx’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about CareDx's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CareDx's cash & equivalents?: CareDx (CDNA) reported cash & equivalents of $78.47M in Q1 2026.
How has CareDx's cash & equivalents changed year-over-year?: CareDx's cash & equivalents decreased by 12.1% year-over-year, from $89.3M to $78.47M.
What is the long-term trend for CareDx's cash & equivalents?: Over 5 years (2020 to 2025), CareDx's cash & equivalents has grown at a -13.3% compound annual growth rate (CAGR), from $134.94M to $65.98M.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.